Quebec, Canada, April 16, 2025 - Feldan Therapeutics announces an investment from Zynext Ventures, the venture capital arm of Zydus Lifesciences.
« This partnership represents a significant step forward for Feldan in our commitment to improving patient quality of life and addressing the major challenges associated with intracellular drug delivery, », said François-Thomas Michaud, CEO.
This financing will support the development of FLD-103, a non-surgical treatment for basal cell carcinoma, as well as the expansion of Feldan's pipeline. Continue reading: Zynext Ventures invests in Feldan Thérapeutiques to accelerate innovation in intracellular drug delivery
